Seiffert Martina M

Show results for

Proteomics (3)
Transcriptomics (2)

Organisms

Archaea (3)
Bacteria (3)
Betaherpesvirinae (3)
Borrelia (3)
Botrytis cinerea (3)
Candida albicans (3)
Clostridium perfringens (3)
Cnidaria (3)
Eukaryota (3)
Fasciola (3)
Fungi (3)
Hepatitis B virus (3)
Human betaherpesvirus 5 (3)
Influenza C virus (3)
Japanese encephalitis virus group (3)
Miscanthus x giganteus (3)
Mycobacterium tuberculosis (3)
Orthoflavivirus (3)
Panicum virgatum (3)
Platyhelminthes (3)
Saccharomyces cerevisiae (3)
Salmonella enterica subsp. enterica (3)
Schizosaccharomyces pombe (3)
Severe acute respiratory syndrome coronavirus 2 (3)
Shigella (3)
Staphylococcus aureus (3)
Streptococcus pneumoniae (3)
Toxoplasma gondii (3)
Tripsacum dactyloides (3)
Homo sapiens (2)

Repository

pride (3)
biostudies-arrayexpress (2)

Tissue

B cell (3)
B-lymphoma cell line (1)
Primary cell (1)

Disease

Chronic lymphocytic leukemia (2)
Lymphoma (1)

Technology Type

Mass Spectrometry (3)
Shotgun proteomics (2)
Bottom-up proteomics (1)
Data-dependent acquisition (1)
Proteogenomics (1)

Publication Date

2024 (2)
2012 (1)
2010 (1)
2017 (1)

Study type

Transcription profiling by array (2)

Release Date

2012 (1)
2010 (1)

Lab affiliation

Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany (3)

Previous page
1 / 1
You're on page 1
Next page

Sort by:

Relevance

Page size

Proteome profiling of blood plasma-derived exosomes in chronic lymphocytic leukemia

In order to analyze differences in the proteome composition of blood plasma-derived exosomes in chronic lymphocytic leukemia (CLL) versus healthy donors, mass spectrometry was conducted for whole protein lysates of plasma-derived exosomes. Abundance of proteins was compared via label free quantifica...

ORGANISM(S): Homo sapiens (Human)

2017-08-09 | PXD004420 | Pride

Longitudinal omics data and preclinical treatment identify proteasome inhibition as therapy for ibrutinib-resistant CLL

Chronic lymphocytic leukemia (CLL) is a malignant lymphoproliferative disorder characterized by the accumulation of small mature B cells in blood and secondary lymphoid tissues. Novel drugs, such as the Bruton tyrosine kinase (BTK) inhibitor ibrutinib, have greatly improved survival of CLL patients,...

ORGANISM(S): Homo sapiens (Human) Mus musculus (Mouse)

2024-12-10 | PXD053512 | Pride

Cll Btki Carfilzomib Proteasome Quantitative proteomics Transcriptomics Ibrutinib-resistance

Longitudinal omics data followed by preclinical treatment studies identify proteasome inhibition as potential salvage strategy for ibrutinib-resistant CLL

ORGANISM(S): Homo sapiens (Human) Mus musculus (Mouse)

2024-12-10 | PXD037314 | Pride

Proteasome inhibitors Cll Proteomics Ibrutinib Multi-omics Drug resistance Tcl-1

MiRNA expression in chronic lymphocytic leukemia

MiRNA expression is known to be deregulated in chronic lymphocytic leukemia (CLL). To get insight into miRNA expression pattern in CLL, we compaired miRNA expression profiling of peripheral blood-derived CLL cells and the healthy donor, peripheral blood-derived B-lymphocytes. A set of differentially...

ORGANISM(S): Homo sapiens

2012-05-01 | E-GEOD-31599 | biostudies-arrayexpress

Genome-Wide Expression Profiling of cultured B-CLL cells

Increased survival of primary B-CLL cells cultured in high cell density: Evidence for activation of pathways also induced by stromal cells. Expression profiles of B-CLL cells before and after three different survival-inducing culture conditions: (1) stromal cell coculture [HCo], (2) stromal cell con...